MIRA INFORM REPORT

 

 

Report Date :

08.04.2014

 

IDENTIFICATION DETAILS

 

Name :

DALAS BIOTECH LIMITED

 

 

Registered Office :

E-292, RIICO Industrial Area, Bhiwadi – 301019, Rajasthan

 

 

Country :

India

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

18.07.1989

 

 

Com. Reg. No.:

17-005056

 

 

Capital Investment / Paid-up Capital :

Rs.44.780 Millions

 

 

CIN No.:

[Company Identification No.]

U24232RJ1989PLC005056

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

JPRD02357F

 

 

PAN No.:

[Permanent Account No.]

AACCS4061Q

 

 

Legal Form :

A Closely Held Public Limited Liability Company

 

 

Line of Business :

Manufacturer and Exporter of Medicines Intermediates.

 

 

No. of Employees :

500 (Approximately)

 

 

RATING & COMMENTS

 

MIRA’s Rating :

B (27)

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Maximum Credit Limit :

USD 1000000

 

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having a moderate track record.

 

Profitability of the company seems to be low during 2013.

 

However, trade relations are reported as fair. Business is active. Payment terms are slow but correct.

 

The company can be considered normal for business dealings with some caution.

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – December 1, 2013

 

Country Name

Previous Rating

(30.09.2013)

Current Rating

(01.12.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

India’s current account deficit for the fiscal third quarter ended September 2013 narrowed to $4.2 billion or 0.9 % of the gross domestic product from $31.9 billion or 6.5 % of GDP a year earlier, thanks to a pick-up in exports and moderation in gold imports. Manufacturing activity and new orders in India showed their strongest growth in a year in February. The news comes as a relief after data showed Asia’s third largest economy grew by a slower-than-expected 4.7 % annually in the three months through December. The HSBC Manufacturing Purchasing Managers’ Index which gauges the business activity of India’s factories but not its’ utilities, rose to 52.5 in February, its highest in a year from 51.4 in January. Overall new orders for factory goods which rose to a one-year high of 54.9 contributed to the surge. China has emerged as India’s biggest trading partner in the current financial year replacing the United Arab Emirates and pushing it to the third spot. India-China trade has reached $49.5 billion with a 8.7 % share in India’s total trade. The US comes second at $46 billion with 8.1 % share during the first nine months of the current financial year.

 

The Reserve Bank of India has granted an additional nine months to the public to exchange currency notes printed before 2005 including Rs 500 and Rs 1,000 denominations, pushing the deadline to January 1, 2015. A day before dates for the Lok Sabha polls were announced, the government decided to hike interest rates on fixed deposit schemes offered by post offices up to 0.2 per cent. The new rates will be effective April, 1. The Supreme Court will resume hearing on March, 11 Nokia’s appeal against a ruling over transferring ownership of its local mobile phones plant which is the subject of a tax dispute to Microsoft Corp.

 

In the last days of the current Government, another scam has surfaced. The defence ministry has ordered a probe into Hindustan Aeronautics Limited’s contracts from Britain’s Rolls-Royce Holdings worth at least $ 1.2 billion. The Central Bureau of Investigation will look into allegations that over $80 million was paid in kickbacks in a deal signed in 2011. India has asked Boeing Co. to find a solution for problems with state-owned Air India’s 787 Dreamliners. The aircraft has experienced a series of malfunctions since its debut in 2011.

 

EXTERNAL AGENCY RATING

 

Rating Agency Name

CRISIL

Rating

Long Term Rating=B+

Rating Explanation

Have high risk of default.

Date

11.11.2013

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

INFORMATION PARTED BY

 

Name :

Mr. Ashish Kaushal

Designation :

Accounts Executive

Contact No.:

91-1493-222527

Date :

07.04.2014

 

 

LOCATIONS

 

Registered Office/ Factory :

E-292, RIICO Industrial Area, Bhiwadi – 301019, Rajasthan, India

Tel. No.:

91-1493-222527

Fax No.:

91-1493-222547

E-Mail :

accounts2@dalasbiotech.com

Website :

www.dalasbiotech.com

Location :

Owned

Locality :

Commercial

 

 

Head Office :

D-34 , 2nd Floor Gulmohar Park, New Delhi-110049, India

 

 

DIRECTORS

 

AS ON 30.09.2013

 

Name :

Mr. Anil Kumar Rajani

Designation :

Director

Address :

D-34, Gulmohar Park, 2nd Floor, New Delhi , India

Date of Appointment :

15.05.1998

DIN No.:

01965248

 

 

Name :

Mr. Atul Rajani

Designation :

Director

Address :

D-34, Gulmohar Park, 2nd Floor, New Delhi , India

Date of Appointment :

26.11.2001

DIN No.:

02664208

 

 

Name :

Ms. Lekha Rajani

Designation :

Director

Address :

D-34, Gulmohar Park, 2nd Floor, New Delhi , India

Date of Appointment :

31.05.2006

DIN No.:

02654340

 

 

KEY EXECUTIVES

 

Name :

Mr. Ashish Kaushal

Designation :

Accounts Executive

 

MAJOR SHAREHOLDERS

 

AS ON 30.09.2013

 

Names of Shareholders

 

No. of Shares

Anil Kumar Rajani

297329

Deepika Rajani

53302

Sangeeta Rajani

49668

Lekha Rajani

47042

Atul Rajani

413

Raj Ram Kumar

20

Asha Yogi

20

Arjun Dass Lund

10

Total

447804

 

Equity Share Break up (Percentage of Total Equity)

 

Category

Percentage

Directors or relatives of Directors

100.00

Total

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Medicines Intermediates.

 

 

Products :

Item Code No. :

350790.09

Product Description

Medicines Intermediates

 

 

Exports :

 

Products :

Finished Goods

Countries :

·         Vietnam

·         Sri Lanka

·         Nigeria

 

 

Imports :

 

Products :

Raw Materials

Countries :

China

 

 

Terms :

 

Selling :

L/C and Credit

 

 

Purchasing :

L/C and Credit

 

 

GENERAL INFORMATION

 

Suppliers :

Not Divulged

 

 

Customers :

End Users

 

Name of Customers: Not Divulged

 

 

No. of Employees :

500 (Approximately)

 

 

Bankers :

Oriental Bank of Commerce, M1/2/3, Connaught Circus, New Delhi – 110001, Delhi, India

 

 

Facilities :

SECURED LOANS

31.03.2013

Rs. In Millions

31.03.2012

Rs. In Millions

Long Term Borrowings

 

 

Term loans from Banks

51.323

114.900

Other Loans and Advances

1.340

2.340

 

 

 

Short Term Borrowings

 

 

Working Capital Loans from Banks

224.010

216.192

 

 

 

Total

276.673

333.432

 

 

 

Banking Relations :

--

 

 

Auditors :

 

Name :

S. Singhal and Company

Chartered Accountant

Address :

E-127, Industrial Area, Bhiwadi – 301019, Rajasthan, India

PAN No.:

AAFFS2873Q

 

 

CAPITAL STRUCTURE

 

AS ON 30.09.2013

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

900000

Equity Shares

Rs.100/- each

Rs.90.000 Millions

100000

Preference Shares

Rs.100/- each

Rs.10.000 Millions

 

 

 

 

 

Total

 

Rs.100.000 Millions

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

447804

Equity Shares

Rs.100/- each

Rs.44.780 Millions

 

 

 

 

 


FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2013

31.03.2012

31.03.2011

I.        EQUITY AND LIABILITIES

 

 

 

(1)Shareholders' Funds

 

 

 

(a) Share Capital

44.780

44.780

34.279

(b) Reserves & Surplus

219.603

208.270

99.289

(c) Money received against share warrants

0.000

0.000

0.000

 

 

 

 

(2) Share Application money pending allotment

0.000

0.000

0.000

Total Shareholders’ Funds (1) + (2)

264.383

253.050

133.568

 

 

 

 

(3) Non-Current Liabilities

 

 

 

(a) long-term borrowings

52.667

117.244

205.458

(b) Deferred tax liabilities (Net)

3.676

0.000

19.950

(c) Other long term liabilities

8.364

10.893

4.299

(d) long-term provisions

1.849

2.032

1.099

Total Non-current Liabilities (3)

66.556

130.169

230.806

 

 

 

 

(4) Current Liabilities

 

 

 

(a) Short term borrowings

246.808

216.192

145.332

(b) Trade payables

259.842

149.491

262.901

(c) Other current liabilities

75.538

51.246

80.420

(d) Short-term provisions

4.479

3.605

6.091

Total Current Liabilities (4)

586.667

420.534

494.744

 

 

 

 

TOTAL

917.606

803.753

859.118

 

 

 

 

II.      ASSETS

 

 

 

(1) Non-current assets

 

 

 

(a) Fixed Assets

 

 

 

(i) Tangible assets

378.661

390.766

353.269

(ii) Intangible Assets

0.000

0.000

0.000

(iii) Capital work-in-progress

6.778

30.880

4.281

(iv) Intangible assets under development

0.000

0.000

0.000

(b) Non-current Investments

0.000

0.000

0.000

(c) Deferred tax assets (net)

0.000

3.976

0.000

(d)  Long-term Loan and Advances

9.339

3.291

3.231

(e) Other Non-current assets

0.000

0.000

0.000

Total Non-Current Assets

394.778

428.913

360.781

 

 

 

 

(2) Current assets

 

 

 

(a) Current investments

0.000

0.000

0.000

(b) Inventories

186.517

112.003

150.096

(c) Trade receivables

281.434

186.444

249.338

(d) Cash and cash equivalents

24.676

24.122

27.924

(e) Short-term loans and advances

8.108

5.666

68.011

(f) Other current assets

22.093

46.605

2.968

Total Current Assets

522.828

374.840

498.337

 

 

 

 

TOTAL

917.606

803.753

859.118

 

 

PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

31.03.2013

31.03.2012

31.03.2011

 

SALES

 

 

 

 

 

Income

1216.477

775.425

868.971

 

 

Other Income

1.797

7.340

2.818

 

 

TOTAL                                         (A)

1218.274

782.765

871.789

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

Cost of Materials Consumed

1058.405

667.374

745.472

 

 

Purchase of Stock-in-trade

6.340

0.000

0.000

 

 

Changes in Inventories of finished goods, work-in-progress and stock-in-trade

(69.231)

18.066

(49.646)

 

 

Employee Benefits Expenses

31.134

32.626

40.574

 

 

Other Expenses

86.978

77.741

84.917

 

 

TOTAL                                         (B)

1113.626

795.807

821.317

 

 

 

 

 

Less

PROFIT/(LOSS) BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B)      (C)

104.648

(13.042)

50.472

 

 

 

 

 

Less

FINANCIAL EXPENSES                         (D)

66.197

48.500

23.283

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D)                                (E)

38.451

(61.542)

27.189

 

 

 

 

 

Less

DEPRECIATION/ AMORTISATION                     (F)

22.215

19.325

13.396

 

 

 

 

 

 

PROFIT/(LOSS) BEFORE TAX (E-F)                   (G)     

16.236

(80.867)

13.793

 

 

 

 

 

Less

TAX                                                                  (H)

7.652

(23.926)

5.443

 

 

 

 

 

 

PROFIT/(LOSS) AFTER TAX (G-H)                    (I)

8.584

(56.941)

8.350

 

 

 

 

 

 

EARNINGS IN FOREIGN CURRENCY

175.400

40.387

NA

 

 

 

 

 

 

Earnings/(Loss) Per Share (Rs.)

19.17

(163.32)

24.73

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2013

31.03.2012

31.03.2011

PAT / Total Income

(%)

0.70

(7.27)

0.96

 

 

 

 

 

Net Profit Margin

(PBT/Sales)

(%)

1.33

(10.43)

1.59

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

1.78

(10.52)

1.61

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.06

(0.32)

0.10

 

 

 

 

 

Debt Equity Ratio

(Total Debt /Networth)

 

1.13

1.32

2.63

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

0.89

0.89

1.01

 

 

FINANCIAL ANALYSIS

[all figures are in Rupees Millions]

 

DEBT EQUITY RATIO

 

Particular

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Share Capital

34.279

44.780

44.780

Reserves & Surplus

99.289

208.270

219.603

Net worth

133.568

253.050

264.383

 

 

 

 

long-term borrowings

205.458

117.244

52.667

Short term borrowings

145.332

216.192

246.808

Total borrowings

350.790

333.436

299.475

Debt/Equity ratio

2.626

1.318

1.133

 

 

 

 

YEAR-ON-YEAR GROWTH

 

Year on Year Growth

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Sales

868.971

775.425

1,216.477

 

 

-10.765

56.879

 

 

 

 

 

NET PROFIT MARGIN

 

Net Profit Margin

31.03.2011

31.03.2012

31.03.2013

 

Rs. In Millions

Rs. In Millions

Rs. In Millions

Sales

868.971

775.425

1216.477

Profit

8.350

(56.941)

8.584

 

0.96%

(7.34%)

0.71%

 

 

 

 

LOCAL AGENCY FURTHER INFORMATION

 

Sr. No.

Check List by Info Agents

Available in Report (Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

Yes

9]

Name of person contacted

Yes

10]

Designation of contact person

Yes

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

-----------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

No

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

Yes

20]

Export / Import details (if applicable)

Yes

21]

Market information

----------

22]

Litigations that the firm / promoter involved in

----------

23]

Banking Details

Yes

24]

Banking facility details

Yes

25]

Conduct of the banking account

----------

26]

Buyer visit details

----------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

Yes

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

No

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

Yes

 

 

FINANCIAL HIGHLIGHTS:

 

·         The turnover of the Company increased to Rs.1216.477 Millions, during the financial year ended on 31st March, 2013, as compared to last turnover of Rs.775.425 Millions, thereby registering a growth of 56% as compared to last year.

 

·         The Profit before tax stood at Rs.16.236 Millions, for the current financial year, as compared to loss of (Rs.80.867 Millions) in the last financial year.

 

·         The profit after tax (PAT) is Rs.8.584 Millions, in the current financial year as compared to loss of (Rs.56.942 Millions) in the last financial year.

 

 

BUSINESS HIGHLIGHTS:

 

The Company has successfully launched, new Product, Amoxicillin, via enzymatic route in the financial year 2012-13. The product was well received in the market resulting thereby increased margin in the current financial year. The Company has been focusing on developing new products during the year under review which will increase the turnover and operating margins of the Company in the coming years.

 

 

UNSECURED LOANS:

 

Particulars

31.03.2013

Rs. In Millions

31.03.2012

Rs. In Millions

Long Term Borrowings

 

 

Loans and Advances from Related Parties

0.004

0.004

 

 

 

Short Term Borrowings

 

 

Other Loans and Advances

22.798

0.000

 

 

 

Total

22.802

0.004

 

 

INDEX OF CHARGE:

 

Sr. No.

Charge ID

Date of Charge Creation/Modification

Charge amount secured

Charge Holder

Address

Service Request Number (SRN)

1

10299543

01/06/2013 *

98,200,000.00

ORIENTAL BANK OF COMMERCE

HARSHA BHAWAN, E-BLOCK, CONNAUGHT PLACE, NEW DELHI, DELHI - 110001, INDIA

B80144157

2

10274373

21/03/2011

250,000,000.00

UNION BANK OF INDIA

SME BRANCH, 173-174 DSIDC, OKHLA INDUSTRIAL AREA
PHASE-I, NEW DELHI, DELHI - 110020, INDIA

B08823544

3

10241193

01/06/2013 *

132,700,000.00

ORIENTAL BANK OF COMMERCE

HARSHA BHAWAN, E-BLOCK, CONNAUGHT PLACE, NEW DELHI, DELHI - 110001, INDIA

B80182876

4

10218856

01/06/2013 *

50,300,000.00

ORIENTAL BANK OF COMMERCE

HARSHA BHAWAN, E-BLOCK, CONNAUGHT PLACE, NEW DELHI, DELHI - 110001, INDIA

B80143563

5

10172622

01/06/2013 *

405,000,000.00

ORIENTAL BANK OF COMMERCE

HARSHA BHAWAN, E-BLOCK, CONNAUGHT PLACE, NEW DELHI, DELHI - 110001, INDIA

B80184807

 

* Date of charge modification

 

 

 

 

 

 

FIXED ASSETS:

 

·         Land

·         Building

·         Plant and Machinery

·         Furniture and Fixture

·         Lab Equipments

·         Computer

·         Office Equipment

·         Vehicle

 


CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                  None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                          None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                          None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.60.32

UK Pound

1

Rs.100.04

Euro

1

Rs.82.65

 

 

INFORMATION DETAILS

 

Information Gathered by :

PLK

 

 

Analysis Done by :

RAS

 

 

Report Prepared by :

NKT

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

4

PAID-UP CAPITAL

1~10

3

OPERATING SCALE

1~10

3

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

3

--PROFITABILIRY

1~10

2

--LIQUIDITY

1~10

3

--LEVERAGE

1~10

3

--RESERVES

1~10

3

--CREDIT LINES

1~10

3

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

YES

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

YES

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

 

 

 

TOTAL

 

27

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

*

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

NB

NEW BUSINESS

 

 

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.